Dr. Dubin has more than 35 years of experience in vaccine research, development and commercialization. Prior to retiring in Feb 2025, he spent 9 years at Takeda Pharmaceuticals where he last served as Vaccine Business Unit President.  In this role, Dr Dubin led a vertically integrated vaccine organization with ~2000 global staff responsible for the research, development, manufacture, commercialization and distribution of new vaccines.  Under his leadership Takeda introduced Qdenga, a novel vaccine against dengue fever in 2022 which is now licensed in many countries around the world.  Prior to joining Takeda, he spent 20 years at GlaxoSmithKline Vaccines where he held the role of Vice President and Head, Global Late Clinical Development. During his career at GSK, Dr Dubin led global teams responsible for the clinical development and licensure of a broad range of vaccines addressing important unmet medical needs, including seasonal influenza (Fluarix Quadravalent and FluLaval Quadravalent), pandemic influenza (Pandemrix and Aprepandrix), meningococcal meningitis (Menhibrix and Nimenrix); human papillomavirus (Cervarix), rotavirus (Rotarix), strep pneumonia (Synflorix), malaria (Mosquirix) and herpes zoster (Shingrix). He also led the development activities of several ongoing vaccine programs (eg TB).

Dr. Dubin holds a Medical degree from the University of Pennsylvania and completed his Adult Internal Medicine residency training at the University of Colorado.  He also completed a fellowship in Clinical Infectious Diseases and a postdoctoral research fellowship in Molecular Virology at the University of Pennsylvania. He served as Adjunct Associate Professor of Medicine at the University of Pennsylvania through 2019.  He holds numerous patents in the vaccine field and has co-authored more than 90 scientific publications.